Morgan Stanley Allovir, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Allovir, Inc. stock. As of the latest transaction made, Morgan Stanley holds 47,380 shares of ALVR stock, worth $21,794. This represents 0.0% of its overall portfolio holdings.

Number of Shares

47,380

Previous 69,952 32.27%

Holding current value

$21,794

Previous $50,000 24.0%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.7 - $0.82 $15,800 - $18,509	-22,572 Reduced 32.27%	47,380 $38,000
Q2 2024 Oct 17, 2024	SELL	$0.72 - $0.82 $204,318 - $232,695	-283,775 Reduced 80.22%	69,952 $50,000
Q2 2024 Aug 14, 2024	SELL	$0.72 - $0.82 $204,318 - $232,695	-283,775 Reduced 80.22%	69,952 $50,000
Q1 2024 Oct 17, 2024	BUY	$0.64 - $0.78 $181,616 - $221,344	283,775 Added 405.67%	353,727 $268,000
Q1 2024 Aug 16, 2024	SELL	$0.64 - $0.78 $101,625 - $123,856	-158,790 Reduced 30.98%	353,727 $268,000
Q1 2024 May 15, 2024	SELL	$0.64 - $0.78 $101,625 - $123,856	-158,790 Reduced 30.98%	353,727 $268,000
Q4 2023 Aug 16, 2024	BUY	$0.68 - $2.39 $300,944 - $1.06 Million	442,565 Added 632.67%	512,517 $348,000
Q4 2023 Feb 13, 2024	SELL	$0.68 - $2.39 $27,989 - $98,374	-41,161 Reduced 7.43%	512,517 $348,000
Q3 2023 Nov 15, 2023	BUY	$2.15 - $3.64 $604,693 - $1.02 Million	281,253 Added 103.24%	553,678 $1.19 Million
Q2 2023 Aug 14, 2023	BUY	$3.17 - $5.82 $271,358 - $498,203	85,602 Added 45.82%	272,425 $926,000
Q1 2023 May 15, 2023	SELL	$3.94 - $7.05 $152,923 - $273,631	-38,813 Reduced 17.2%	186,823 $736,000
Q4 2022 Feb 14, 2023	SELL	$4.7 - $9.98 $831,430 - $1.77 Million	-176,900 Reduced 43.95%	225,636 $1.16 Million
Q3 2022 Nov 14, 2022	BUY	$4.13 - $8.79 $1.08 Million - $2.3 Million	261,319 Added 185.05%	402,536 $3.18 Million
Q2 2022 Oct 27, 2022	BUY	$3.26 - $7.06 $160,242 - $347,027	49,154 Added 53.39%	141,217 $551,000
Q2 2022 Aug 15, 2022	BUY	$3.26 - $7.06 $160,242 - $347,027	49,154 Added 53.39%	141,217 $551,000
Q1 2022 Oct 27, 2022	SELL	$6.75 - $13.52 $331,789 - $664,562	-49,154 Reduced 34.81%	92,063 $622,000
Q1 2022 May 13, 2022	BUY	$6.75 - $13.52 $292,410 - $585,686	43,320 Added 88.87%	92,063 $622,000
Q4 2021 Feb 14, 2022	SELL	$12.94 - $25.99 $70,937 - $142,477	-5,482 Reduced 10.11%	48,743 $632,000
Q3 2021 Nov 15, 2021	BUY	$16.97 - $25.06 $920,198 - $1.36 Million	54,225 New	54,225 $1.36 Million

Others Institutions Holding ALVR

# of Institutions

Shares Held

44.6M

Call Options Held

14.9K

Put Options Held

200

View Full List

About Allovir, Inc.

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $42.8M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

More about ALVR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account